The Strongest Half-Year Report in Dizal Pharma's History: Behind Its First Commercialization Profit

Another innovative pharmaceutical company's earnings report has ignited market enthusiasm.

On August 22, Dizal Pharma released its 2025 half-year report, which it called the “strongest half-year report” in its history.

Specifically, revenue in the first half reached a record high of RMB 355 million, representing a year-on-year increase of 74.4%. Among this, the second quarter performed particularly strongly, suggesting that the company still has plenty of momentum.

While revenue increased, losses continued to narrow: net loss decreased 12% year on year.

In fact, in the first half of this year, Dizal Pharma achieved commercialization profit for the first time: in other words, revenue already covered costs beyond R&D (including sales and management expenses).

This breakthrough means that Dizal has officially stepped into the stage of “profits generated from drug sales.” The test of “whether it can be profitable” has become a thing of the past, and the logic of the profitability cycle has already been established. What remains is only time for results to gradually materialize.

It is not difficult to see that Dizal is accelerating in the right direction, with a pace that is clear and steady. For this reason, the market has responded positively to this financial report.

First-Ever Commercialization Profit

This half-year report, which can be described as the “strongest,” has enabled the market to clearly capture many certainties about Dizal.

The most direct one is its remarkable “stability.” As of the end of June, the company's cash and cash equivalents reached RMB 2.251 billion, a year-on-year increase of 1.72 times. Such abundant cash reserves not only provide a solid foundation to withstand industry fluctuations but also give the company strong confidence to expand operations and lay out its long-term development.

Of course, the highlights of this half-year report are not only about “stability,” but also about clear “progress.” As mentioned above, while revenue continues to grow and losses continue to narrow, the company has also achieved commercialization profit for the first time. This undoubtedly releases a very clear signal: Dizal is accelerating toward the overall profitability cycle.

The underlying logic is not difficult to understand: for pharmaceutical companies, as sales scale continues to expand, the combination of efficient execution and scale effects often drives “sales profit” into a rapid growth channel.

Dizal's performance proves this. Over the past several years, the market has clearly observed that while sales performance has grown rapidly, the company's expense ratios have shown a straight-line decline; this favorable trend continued in the first half of this year, with the selling expense ratio down 24 percentage points year on year.

From a long-term perspective, the market penetration of its core products Sunvozertinib and Golidocitinib continues to deepen, with growth potential far from reaching its ceiling. As sales scale continues to expand, the company's efficient operating system and scale effects will continue to release, leaving further room for expense ratios to decline.

All this means that Dizal has steadily entered a healthy and rapid development path in which “drug sales profit gradually covers R&D investment, and its internal cash-generating ability continues to strengthen.” The path to overall profitability is becoming increasingly clear.

Internationalization Accelerates

For innovative pharmaceutical companies like Dizal, the current market focus is no longer only on financial performance, but more on deeper breakthroughs at the business level. The latest half-year report reveals an especially positive signal: its internationalization process is accelerating.

In 2025, the U.S. FDA's approval of Sunvozertinib was undoubtedly the most eye-catching milestone. This achievement directly validated Dizal's “fully independent” internationalization capability: from conducting overseas clinical trials of Sunvozertinib, to subsequent submissions and eventual approval, the entire process was completed independently by the company.

This means that compared with most domestic pharmaceutical companies, Dizal's path to globalization is more flexible and has the potential to create greater value. From the company's past strategic statements, it has always sought to retain as much of the complete global rights to its products as possible in order to maximize returns. The core prerequisite for achieving this is, of course, “independent control.” After all, without independent global clinical operation capabilities, companies can only rely on external partners to advance, often having to give up more rights. For Dizal, with its independent capability, it can maintain control during globalization without being restricted by partners. Therefore, “creating greater value through internationalization” has become its clear and visible trump card.

After its fully independent internationalization capability has been validated, it is only natural for Dizal to push forward more international key clinical trials. The market's earlier question was: when will this “internationalization trump card” press the “accelerate button”? This half-year report disclosure provides a clear answer.

Looking forward, as R&D continues to accelerate, Dizal will undoubtedly continue to unleash potential in both domestic and global markets, bringing more new expectations to the market.

Riding a “Cheat-Mode” Growth Trend

The significant acceleration of R&D progress is another key signal released by Dizal's latest half-year report.

According to the report, Dizal disclosed four Phase III clinical trials, two of which were newly disclosed in this half-year report—enough to prove that it is in a stage of full acceleration in R&D.

The confidence behind this acceleration comes from its proven R&D strength and from solid financial support. As the first pre-profit company to complete refinancing under the STAR Market “Eight Rules” framework, Dizal successfully raised RMB 1.796 billion, laying a strong financial foundation for the efficient development of its core pipeline products.

Of course, for innovative pharmaceutical companies, the focus has never been on the number of pipeline projects but on their quality. The market's higher expectations for Dizal's accelerated R&D come mainly from three dimensions.

1. Pipelines with FIC/BIC potential, continuously gaining international recognition.

   This is evident from appearances at international academic conferences and regulatory recognition. For example, Birelentinib (DZD8586) not only secured an oral presentation slot at its first appearance at the ASCO conference, but also once again presented orally at the 18th International Conference on Malignant Lymphoma (ICML). This year alone, Dizal's pipeline has received four oral presentations at top international academic conferences. More importantly, thanks to its outstanding clinical data, Birelentinib has obtained the U.S. FDA's “Fast Track designation.” Based on its excellent performance, Birelentinib has already launched its first Phase III clinical trial in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (r/r CLL/SLL).

   Another blockbuster pipeline candidate, DZD6008, made its debut at this year's ASCO conference, demonstrating its potential to address the resistant EGFR TKI non-small cell lung cancer (NSCLC) market.

2. High expandability of pipelines, with stronger certainty of R&D input-output.

   A distinctive feature of Dizal's pipeline is the broad expansion space for indications of individual assets.

   Take Sunvozertinib as an example. It is not only the only small-molecule targeted drug included in the NCCN international lung cancer guidelines for previously treated EGFR ex20ins NSCLC, but its global confirmatory Phase III first-line clinical trial (WU-KONG28) recently completed enrollment. The global validation of its BIC potential is highly anticipated. Moreover, Dizal has made further arrangements. One of the newly disclosed Phase III clinical trials this year is Sunvozertinib as adjuvant therapy for NSCLC with EGFR ex20ins or PACC mutations after surgery. If successful, its potential ceiling will be raised further.

   Golidocitinib is similar. With its globally first-in-class mechanism of action, it has the potential to cover peripheral T-cell lymphoma (PTCL) entirely, and it has also shown application potential in clinical studies combining with PD-1 inhibitors for non-small cell lung cancer.

   This strong expandability means that each R&D investment can unlock clearer market value, making output certainty more pronounced.

3. Focused specialization layout, building a competitive moat.

   It is worth noting that Dizal's pipeline portfolio is not scattered but forms synergy around core areas: its current R&D focus is on lung cancer and hematologic malignancies. Among the nearly 20 studies presented or soon to be presented at international conferences this year, nearly 80% focus on lung cancer, with the rest focusing on blood cancers.

   The logic behind this is clear: it allows the company to deepen and strengthen in specialist fields, consolidating technical barriers, while also maximizing the synergies of its pipeline matrix, forming a positive cycle between R&D and commercialization efficiency.

From commercialization scale-up to full validation of its independent internationalization capability, Dizal has built a complete closed-loop logic for transforming into a biopharma. The acceleration of R&D at this moment not only means the pipeline will continue to deepen but also heralds stronger momentum for commercialization expansion and internationalization.

Overall, Dizal is undoubtedly on a “cheat-mode” growth trend: revenue is growing rapidly, selling and administrative expense ratios are steadily declining, efficient R&D continues to deliver results, profitability is only a matter of time, and the ceiling for value growth will continue to rise.